Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INOGet Free Report) have been assigned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $12.40.

A number of equities analysts have recently issued reports on the company. HC Wainwright reduced their price target on Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating on the stock in a research report on Monday. Oppenheimer decreased their price target on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research note on Monday, November 18th. JMP Securities reissued a “market outperform” rating and issued a $18.00 price target on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. Finally, Royal Bank of Canada dropped their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Friday, November 15th.

Read Our Latest Report on Inovio Pharmaceuticals

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its stake in shares of Inovio Pharmaceuticals by 177.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 3,630 shares during the last quarter. SG Americas Securities LLC acquired a new position in Inovio Pharmaceuticals in the third quarter valued at approximately $71,000. The Manufacturers Life Insurance Company purchased a new stake in Inovio Pharmaceuticals in the 2nd quarter worth approximately $82,000. MetLife Investment Management LLC increased its holdings in shares of Inovio Pharmaceuticals by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 8,546 shares in the last quarter. Finally, Atom Investors LP acquired a new stake in Inovio Pharmaceuticals during the third quarter valued at $103,000. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Price Performance

Shares of INO stock opened at $1.87 on Friday. The stock’s 50-day moving average is $3.35 and its 200 day moving average is $6.05. Inovio Pharmaceuticals has a 1-year low of $1.74 and a 1-year high of $14.75. The company has a market cap of $48.81 million, a P/E ratio of -0.90 and a beta of 0.84.

About Inovio Pharmaceuticals

(Get Free Report

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Read More

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.